Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Medpace Holdings Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.05 (market cap $12.87B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Medpace Holdings Inc for 14 Days on average.
| EMB | MEDP | |
|---|---|---|
Market Cap | $12.87B | $16.82B |
Volume | 14,946,002 | 223,093 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $630.19 |
52-Week Low | $90.14 | $393.42 |
Typical Hold Time | 50 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at oversold levels. Recent dividend declarations of $0.41-$0.44 per share provide income support, though key valuation ratios remain unavailable for analysis. Technical indicators suggest the stock is testing support levels near $90-$91.
The outlook remains cautious given the bearish technical momentum and limited fundamental data visibility. Income investors may find value in the dividend yield, but the lack of current financial metrics and bearish technical signals suggest near-term pressure. Market sentiment appears mixed with fixed income ETFs seeing inflows while emerging market bonds face AI-driven yield pressures.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
